211 related articles for article (PubMed ID: 28566016)
21. Insights into Dynamic Mechanism of Ligand Binding to Peroxisome Proliferator-Activated Receptor γ toward Potential Pharmacological Applications.
Miyamae Y
Biol Pharm Bull; 2021; 44(9):1185-1195. PubMed ID: 34471046
[TBL] [Abstract][Full Text] [Related]
22. Molecular Recognition of PPARγ by Kinase Cdk5/p25: Insights from a Combination of Protein-Protein Docking and Adaptive Biasing Force Simulations.
Mottin M; Souza PC; Skaf MS
J Phys Chem B; 2015 Jul; 119(26):8330-9. PubMed ID: 26047365
[TBL] [Abstract][Full Text] [Related]
23. Discovery of a novel selective PPARγ ligand with partial agonist binding properties by integrated in silico/in vitro work flow.
Kouskoumvekaki I; Petersen RK; Fratev F; Taboureau O; Nielsen TE; Oprea TI; Sonne SB; Flindt EN; Jónsdóttir SÓ; Kristiansen K
J Chem Inf Model; 2013 Apr; 53(4):923-37. PubMed ID: 23432662
[TBL] [Abstract][Full Text] [Related]
24. Molecular Modeling Approach to Study the PPARγ-Ligand Interactions.
Al Sharif M; Tsakovska I; Alov P; Vitcheva V; Diukendjieva A; Pajeva I
Methods Mol Biol; 2019; 1966():261-289. PubMed ID: 31041755
[TBL] [Abstract][Full Text] [Related]
25. Molecular docking, 3D-QSAR and structural optimization on imidazo-pyridine derivatives dually targeting AT1 and PPARg.
Zhang J; Hao QQ; Liu X; Jing Z; Jia WQ; Wang SQ; Xu WR; Cheng XC; Wang RL
Oncotarget; 2017 Apr; 8(15):25612-25627. PubMed ID: 28445965
[TBL] [Abstract][Full Text] [Related]
26. The conserved residue Phe273(282) of PPARalpha(gamma), beyond the ligand-binding site, functions in binding affinity through solvation effect.
Yue L; Ye F; Xu X; Shen J; Chen K; Shen X; Jiang H
Biochimie; 2005 Jun; 87(6):539-50. PubMed ID: 15935279
[TBL] [Abstract][Full Text] [Related]
27. The nuclear receptor-coactivator interaction surface as a target for peptide antagonists of the peroxisome proliferator-activated receptors.
Mettu NB; Stanley TB; Dwyer MA; Jansen MS; Allen JE; Hall JM; McDonnell DP
Mol Endocrinol; 2007 Oct; 21(10):2361-77. PubMed ID: 17595321
[TBL] [Abstract][Full Text] [Related]
28. Mechanisms of Nelumbinis folium targeting PPARγ for weight management: A molecular docking and molecular dynamics simulations study.
Wong AR; Yang AWH; Gill H; Lenon GB; Hung A
Comput Biol Med; 2023 Nov; 166():107495. PubMed ID: 37742414
[TBL] [Abstract][Full Text] [Related]
29. Ligands for the Nuclear Peroxisome Proliferator-Activated Receptor Gamma.
Sauer S
Trends Pharmacol Sci; 2015 Oct; 36(10):688-704. PubMed ID: 26435213
[TBL] [Abstract][Full Text] [Related]
30. Pharmacophore modeling improves virtual screening for novel peroxisome proliferator-activated receptor-gamma ligands.
Lewis SN; Garcia Z; Hontecillas R; Bassaganya-Riera J; Bevan DR
J Comput Aided Mol Des; 2015 May; 29(5):421-39. PubMed ID: 25616366
[TBL] [Abstract][Full Text] [Related]
31. Structural basis of the transactivation deficiency of the human PPARγ F360L mutant associated with familial partial lipodystrophy.
Lori C; Pasquo A; Montanari R; Capelli D; Consalvi V; Chiaraluce R; Cervoni L; Loiodice F; Laghezza A; Aschi M; Giorgi A; Pochetti G
Acta Crystallogr D Biol Crystallogr; 2014 Jul; 70(Pt 7):1965-76. PubMed ID: 25004973
[TBL] [Abstract][Full Text] [Related]
32. Probing intermolecular interactions and binding stability of kaempferol, quercetin and resveratrol derivatives with PPAR-γ: docking, molecular dynamics and MM/GBSA approach to reveal potent PPAR- γ agonist against cancer.
Lokhande KB; Ballav S; Yadav RS; Swamy KV; Basu S
J Biomol Struct Dyn; 2022 Feb; 40(3):971-981. PubMed ID: 32954977
[TBL] [Abstract][Full Text] [Related]
33. In silico and in vitro analysis of PPAR - α / γ dual agonists: Comparative evaluation of potential phytochemicals with anti-obesity drug orlistat.
Mandal SK; Kumar BK; Sharma PK; Murugesan S; Deepa PR
Comput Biol Med; 2022 Aug; 147():105796. PubMed ID: 35809408
[TBL] [Abstract][Full Text] [Related]
34. Development of an In Vitro Screening Platform for the Identification of Partial PPARγ Agonists as a Source for Antidiabetic Lead Compounds.
Porskjær Christensen L; Bahij El-Houri R
Molecules; 2018 Sep; 23(10):. PubMed ID: 30248999
[TBL] [Abstract][Full Text] [Related]
35. A rapid, homogeneous, fluorescence polarization binding assay for peroxisome proliferator-activated receptors alpha and gamma using a fluorescein-tagged dual PPARalpha/gamma activator.
Seethala R; Golla R; Ma Z; Zhang H; O'Malley K; Lippy J; Cheng L; Mookhtiar K; Farrelly D; Zhang L; Hariharan N; Cheng PT
Anal Biochem; 2007 Apr; 363(2):263-74. PubMed ID: 17335769
[TBL] [Abstract][Full Text] [Related]
36. Peroxisome Proliferator-Activated Receptor γ (PPARγ) and Ligand Choreography: Newcomers Take the Stage.
Garcia-Vallvé S; Guasch L; Tomas-Hernández S; del Bas JM; Ollendorff V; Arola L; Pujadas G; Mulero M
J Med Chem; 2015 Jul; 58(14):5381-94. PubMed ID: 25734377
[TBL] [Abstract][Full Text] [Related]
37. Discovery of Isoquinolinoquinazolinones as a Novel Class of Potent PPARγ Antagonists with Anti-adipogenic Effects.
Jin Y; Han Y; Khadka DB; Zhao C; Lee KY; Cho WJ
Sci Rep; 2016 Oct; 6():34661. PubMed ID: 27695006
[TBL] [Abstract][Full Text] [Related]
38. Mode of peroxisome proliferator-activated receptor γ activation by luteolin.
Puhl AC; Bernardes A; Silveira RL; Yuan J; Campos JL; Saidemberg DM; Palma MS; Cvoro A; Ayers SD; Webb P; Reinach PS; Skaf MS; Polikarpov I
Mol Pharmacol; 2012 Jun; 81(6):788-99. PubMed ID: 22391103
[TBL] [Abstract][Full Text] [Related]
39. The influence of peroxisome proliferator-activated receptor γ (PPARγ) ligands on cancer cell tumorigenicity.
Yousefnia S; Momenzadeh S; Seyed Forootan F; Ghaedi K; Nasr Esfahani MH
Gene; 2018 Apr; 649():14-22. PubMed ID: 29369787
[TBL] [Abstract][Full Text] [Related]
40. Study of the interactions between Edaglitazone and Ciglitazone with PPARγ and their antiplatelet profile.
Muñoz-Gutiérrez C; Sepúlveda C; Caballero J; Palomo I; Fuentes E
Life Sci; 2017 Oct; 186():59-65. PubMed ID: 28757415
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
